Combination Antibody Therapy for Cancer Treatment Overview

  • ID: 3721624
  • Report
  • Region: Global
  • 116 Pages
  • Insight Pharma Reports
1 of 4

FEATURED COMPANIES

  • BioPlan Associates, Inc.
  • Eureka Therapeutics
  • Lonza Group
  • Peregrine Pharmaceuticals
  • Symphogen
  • MORE
Recombinant antibodies have been the shining jewels in the firmament of the pharma industry for almost the last two decades. They have returned billions of dollars in sales, and if their performance has not been the unalloyed triumph that was foreseen at their inception, they have, at least in some instances, produced impressive gains in patient response. Today they are one of the most fundamental strategies for treating patients with hematological malignancies and solid tumors. This report explores the next level of therapy, combining antibodies with additional agents.

The report consists of eight chapters that address different aspects of the issue of combined antibody therapy - past, present, and future, topics include:

- A brief review of the clinical efficacy and market status of currently approved antibody-based drugs for cancer therapy
- Outlook for combination antibody therapeutics
- Targeted Antibody Therapeutics & Immuno-Antibody Therapeutics
- Development and Current Products
- Combination of Chemotherapy and Immuno-antibody therapeutics
- Combinations of immune-antibodies
- Immuno- antibody therapeutics in the marketplace
- Fusion Antibody Therapeutics
- Multitargeted and Polyfunctional Antibody Therapeutics
- Patent Expiration and the Rise of Biosimilars
- Biosimilar antibodies in the market
- Deals and the Marketplace
- Interviews with Leading Experts:

Interview with Esper Boel, SVP, head of discovery; Ivan Horak, CSO; and Mads Laustsen, CMO at Symphogen
Interview with Eric S. Langer, Managing Partner, BioPlan Associates, Inc.
Interview with Dr. Laurent Ducry, Group Leader Bioconjugates R&D, Lonza, Valais, Switzerland
Interview with Dr. Cheng Liu, CEO, Eureka Therapeutics
Interview with Steve King, President, Peregrine Pharma
Survey with data from Industry Representatives Concerning Developments in Antibody Technology
READ MORE
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • BioPlan Associates, Inc.
  • Eureka Therapeutics
  • Lonza Group
  • Peregrine Pharmaceuticals
  • Symphogen
  • MORE
Executive Summary

Background

Topics covered in this report

- Chapter 1
- Chapter 2
- Chapter 3
- Chapter 4
- Chapter 5
- Chapter 6
- Chapter 7
- Chapter 8
- Outlook for combination antibody therapeutics

Chapter 1
- Introduction, Scope and Objectives
- A brief review of the clinical efficacy and market status of currently approved antibody-based drugs for cancer therapy
- Bevacizumab
- Necitumumab
- Dinutuximab.
- Nivolumab.
- Blinatumomab
- Pembrolizumab
- Ramucirumab
- Obinutuzumab
- Ado-trastuzumab emtansine
- Ipilimumab: Immune checkpoint inhibitors
- Pertuzumab.
- Opportunities and challenges for future development
- 1.2.1. A need for targets.
- Safety concerns.
- Objectives and outlook for combination antibody therapy
- 1.3.1. Overcoming resistance to anti-cancer agents.
- 1.3.2. Uncertainties in combined antibody therapy.
- 1.4. Summary

Chapter 2
- Targeted Antibody Therapeutics
- 2.1. The unstable cancer genome.
- 2.2. The epigenome.
- 2.3. Chemotherapy treatment combined with antibodies
- 2.4. Combinations of targeted antibodies
- 2.5. Targeted antibody therapeutics and the marketplace
- 2.6. Targeted antibody therapeutics in the clinic
- 2.7. Summary

Chapter 3
- Immuno-Antibody Therapeutics
- Development and Current Products
- Combination of Chemotherapy and Immuno-antibody therapeutics
- Combinations of immune-antibodies
- Immuno- antibody therapeutics in the marketplace
- 3.5. Immuno- antibody therapeutics in the clinic
- Summary

Chapter 4
- Fusion Antibody Therapeutics
- 4.1. Antibody Drug Conjugates (ADCs)
- Antibody Biologic Constructs (ABCs)
- Immunocytokines
- Fusion antibodies in combination with other drugs
- Summary

Chapter 5
- Multitargeted and Polyfunctional Antibody Therapeutics
- 5.1. Status and clinical studies of Bispecific and bi-targeted antibodies
- 5.2. Recombinant polyclonal antibodies
- 5.3. Combination therapy
- 5.4. Challenges in manufacturing
- 5.5. Regulatory areas: Challenges
- 5.5. Summary

Chapter 6
- Patent Expiration and the Rise of Biosimilars
- 6.1. Introduction
- Biosimilar antibodies in the market
- Target products nearing patent expiration
- Prospects for biobetters
- A bright future for modified antibodies
- Summary

Chapter 7
- Deals and the Marketplace
- 7.1. Mergers and acquisitions
- 7.3. The Mother of all Mergers
- 7.4. Summary

Chapter 8
- Strategic Issues
- 8.1. Balancing basic and clinical research
- 8.1.1. A troubled time for the life sciences
- 8.1.2. Shoddy and questionable research
- 8.1.3. A resolution to the funding crisis?
- 8.1.4. Promising areas of discovery in cancer combination therapies
- 8.1.4.1. CTLA-4.
- 8.1.4.2. CD-38.
- 8.1.4.3. Rectal cancer therapies
- New approaches to oncology: Diagnostics versus therapeutics
- 8.2.1. The frustrating search for effective disease biomarkers
- 8.2.2. A mix of approaches to cancer biomarker discovery.
- 8.2.3. Three approaches to immunodiagnostic cancer markers
- 8.2.3.1. The first is the traditional approach of characterization of a single cancer-related marker and its validation as an immunodiagnostic test.
- 8.2.3.2. The second approach has evolved as sophisticated instrumentation for multiplexing has become more widely available.
- 8.2.3.3. Yet a third approach is a more indirect one - identifying tumor-specific antibodies in the serum of affected individuals.
- 8.2.4. Current cancer markers in use
- 8.3. Opportunities and pitfalls
- 8.3.1. NCI-MATCH trials
- 8.3.2. A wide range of treatments offers better odds of survival.
- Summary

Chapter 9
- Interviews with Experts in the Field
- 9.1. Interview with Esper Boel, SVP, head of discovery; Ivan Horak, CSO; and Mads Laustsen, CMO at Symphogen
- 9.2. Interview with Eric S. Langer, Managing Partner, BioPlan Associates, Inc.
- 9.3. Interview with Dr. Laurent Ducry, Group Leader Bioconjugates R&D, Lonza, Valais, Switzerland
- 9.4. Interview with Dr. Cheng Liu, CEO, Eureka Therapeutics
- 9.5. Interview with Steve King, President, Peregrine Pharma

Chapter 10
- Questionnaire put to Industry Representatives Concerning Developments in Antibody Technology
- References
- About

Figures
- Figure 1.1.7.1.
- Figure 1.1.8.1. Timeline for development of ipilimumab.
- Figure 1.1.11.1. Binding sites on human epidermal growth factor receptor 2 (HER2) for FDA-approved HER2-directed therapies
- Figure 2.1. Mechanisms that drive drug resistance in cancer cells
- Figure 2.2.1. Depiction of the Primary Mechanisms that Enable Cancer Cells to Become Drug Resistant
- Figure 3.1.1. Flash Gordon Comic Strip from the 1950s.
- Figure 3.1. The Il-2 pathway.
- Figure 3.2.1. MAPK Pathway and Mechanism of Vemurafenib
- Figure 3.3.1. Domain Architecture and Affinity Purification of a scFv:CD40L Fusion Proteins
- Figure 5.1.1. Alternative possibilities for bispecific Antibodies.
- Figure 8.2.1.1. Biomarker discovery over the last 30 years
- Figure 8.4.1. Rate of new drug approvals.

Tables
- Table 1.1. FDA-Approved Epigenetic Therapies
- Table 3.1.1. Currently Approved Non-mAb Anticancer Immunotherapeutics.
- Table 4.1.1. Seattle Genetics ADCs in clinical trials
- Table 5.2.1. Examples of Oligoclonal and polyclonal antibody therapeutics in development.
- Table 7.1: Merger and Acquisition Trends
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
- BioPlan Associates, Inc.
- Eureka Therapeutics
- Lonza Group
- Peregrine Pharmaceuticals
- Symphogen
Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown
Adroll
adroll